seed
Stage
2021
Founded
1
Investors
About
ParcelBio develops a proprietary mRNA platform, APEXm™, that enhances protein expression potency and durability to enable durable mRNA medicines for applications including in vivo CAR-T therapies, oncology, autoimmune diseases, and therapeutic protein delivery.
Explore ParcelBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.